drugset / Trial / NCT02014116
A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.
Timeline
- Start
- 2013-11-26
- Primary completion
- 2017-04-07
- Completion
- 2018-10-05
Outcome
Outcome not reported
Stopped: “This trial was terminated early based on the lack of sufficient clinical efficacy observed.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3009120 | Small molecule | 50 mg | Oral |
| Subject | LY3009120 | Small molecule | 100 mg | Oral |
| Subject | LY3009120 | Small molecule | 200 mg | Oral |
| Subject | LY3009120 | Small molecule | 300 mg | Oral |
| Subject | LY3009120 | Small molecule | 400 mg | Oral |
| Subject | LY3009120 | Small molecule | 500 mg | Oral |